Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ceftazidime

FDA-approved product (injectable, injection), marketed as Ceftazidime, Ceftazidime In Dextrose Container, Ceptaz and 7 more.

Registered studies
50+
Lab records
324
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Ceftazidime
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Infection
  • Parametritis
  • Peritonitis
  • Pneumonia
  • Pyelonephritis
  • Urinary tract infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Third-generation cephalosporins
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01DD02

Repurposing investigation

Ceftazidime is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA94.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli>99% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae60.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis53.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 5 of 5 lab records
  • E. coli: measured active in 41 of 47 lab records
  • K. pneumoniae: measured active in 111 of 272 lab records
Open Ceftazidime in ChEMBL Registered studies below
Show the latest 150 of 324 laboratory records, with sources

Loading records…

Every record is in ChEMBL, linked above. “Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ceftazidime with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Imipenem/Cilastatin/Relebactam (IMI/REL) in Treatment of CRE Infections

    NCT04785924 · start 2021-06-07

    Registered record
    Registry ID
    NCT04785924
    Conditions
    Carbapenem-Resistant Enterobacteriaceae Infection; KPC; Gram-Negative Bacterial Infections; Antibiotic Resistant Infection
    Interventions
    Imipenem+Relebactam
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2021-06-07
    Completion
    2023-01-12
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarbapenem-Resistant Enterobacteriaceae Infection; KPC; Gram-Negative Bacterial Infections; Antibiotic Resistant Infection
    InterventionImipenem+Relebactam
    PhasePhase 4
    Registry statusWithdrawn

  • Population Pharmacokinetics of Commonly Used Antimicrobial Agents in Children of Bacterial Meningitis With Augmented Renal Clearance

    NCT04771884 · start 2020-10-01

    Registered record
    Registry ID
    NCT04771884
    Conditions
    Bacterial Meningitis; Augmented Renal Clearance
    Interventions
    meropenem vancomycin ceftazidime ceftriaxone ceftizoxime linezolid
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2020-10-01
    Completion
    2026-03-20
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Meningitis; Augmented Renal Clearance
    Interventionmeropenem vancomycin ceftazidime ceftriaxone ceftizoxime linezolid
    PhaseNot recorded
    Registry statusUnknown

  • Ceftazidime in Burn Children

    NCT03881800 · start 2020-02-19

    Registered record
    Registry ID
    NCT03881800
    Conditions
    Burned Children; Ceftazidime Treatment
    Interventions
    titration- blood sample
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-02-19
    Completion
    2020-11-11
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBurned Children; Ceftazidime Treatment
    Interventiontitration- blood sample
    PhaseNot recorded
    Registry statusCompleted

  • Is Cefazolin, Ceftazidime and Ciprofloxacin Dosing Optimal in Hemodialysis Patients?

    NCT04319328 · start 2019-10-18

    Registered record
    Registry ID
    NCT04319328
    Conditions
    Hemodialysis Complication; Infectious Disease; End Stage Renal Disease
    Interventions
    Cefazolin; Ceftazidime
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2019-10-18
    Completion
    2024-04-30
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHemodialysis Complication; Infectious Disease; End Stage Renal Disease
    InterventionCefazolin; Ceftazidime
    PhaseNot recorded
    Registry statusCompleted

  • A Trial to Evaluate the Pharmacokinetics and Safety of AVYCAZ(R) in Combination With Aztreonam

    NCT03978091 · start 2019-07-09

    Registered record
    Registry ID
    NCT03978091
    Conditions
    Bacterial Infection
    Interventions
    AZACTAM; Ceftazidime-Avibactam
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2019-07-09
    Completion
    2020-11-23
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Infection
    InterventionAZACTAM; Ceftazidime-Avibactam
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Safety and Efficacy of Vancomycin Plus Beta-lactams

    NCT03776409 · start 2018-12-12

    Registered record
    Registry ID
    NCT03776409
    Conditions
    Critical Illness
    Interventions
    vancomycin plus piperacillin/tazobactam; vancomycin plus other beta-lactams
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2018-12-12
    Completion
    2020-05-30
    Enrolment
    700

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCritical Illness
    Interventionvancomycin plus piperacillin/tazobactam; vancomycin plus other beta-lactams
    PhaseNot recorded
    Registry statusCompleted

  • Real-World Observational Study Of Zavicefta to Characterize Use Patterns

    NCT03923426 · start 2018-11-27

    Registered record
    Registry ID
    NCT03923426
    Conditions
    Infection
    Interventions
    Zavicefta Treatment
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2018-11-27
    Completion
    2022-03-28
    Enrolment
    572

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection
    InterventionZavicefta Treatment
    PhaseNot recorded
    Registry statusCompleted

  • Usage of Meropenem/Gentamicin Versus Ceftazidime/Avibactam in ARDS

    NCT04402359 · start 2018-07-05

    Registered record
    Registry ID
    NCT04402359
    Conditions
    Ventilator Associated Pneumonia
    Interventions
    meropenem; ceftazidime 2 grams and avibactam 500; ventilator
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2018-07-05
    Completion
    2019-12-30
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVentilator Associated Pneumonia
    Interventionmeropenem; ceftazidime 2 grams and avibactam 500; ventilator
    PhaseNot recorded
    Registry statusCompleted

  • Ceftobiprole in the Treatment of Pediatric Patients With Pneumonia

    NCT03439124 · start 2017-11-27

    Registered record
    Registry ID
    NCT03439124
    Conditions
    Community-acquired Pneumonia (CAP); Hospital-acquired Pneumonia (HAP)
    Interventions
    ceftobiprole medocaril; IV standard-of-care cephalosporin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-11-27
    Completion
    2020-03-16
    Enrolment
    138

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCommunity-acquired Pneumonia (CAP); Hospital-acquired Pneumonia (HAP)
    Interventionceftobiprole medocaril; IV standard-of-care cephalosporin
    PhasePhase 3
    Registry statusCompleted

  • Phase 1 Study to Evaluate DDI, PK, Safety, Tolerability of SPR741

    NCT03376529 · start 2017-11-10

    Registered record
    Registry ID
    NCT03376529
    Conditions
    Healthy Volunteers
    Interventions
    SPR741; Ceftazidime; Piperacillin/tazobactam; Aztreonam
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-11-10
    Completion
    2017-12-20
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionSPR741; Ceftazidime; Piperacillin/tazobactam; Aztreonam
    PhasePhase 1
    Registry statusCompleted

  • BetaLACTA® Test for Early De-escalation of Empirical Carbapenems in Pulmonary, Urinary and Bloodstream Infections in ICU

    NCT03147807 · start 2017-10-20

    Registered record
    Registry ID
    NCT03147807
    Conditions
    Pneumonia; Urinary Tract Infections; Bloodstream Infection
    Interventions
    betaLACTA® rapid diagnostic test
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2017-10-20
    Completion
    2019-10-20
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPneumonia; Urinary Tract Infections; Bloodstream Infection
    InterventionbetaLACTA® rapid diagnostic test
    PhaseNot applicable
    Registry statusCompleted

  • Study of Ceftazidime-Avibactam Blood Concentrations in Intensive Care Unit Patients With Renal Failure Requiring Continuous Dialysis

    NCT03243864 · start 2017-03-13

    Registered record
    Registry ID
    NCT03243864
    Conditions
    Renal Failure; Bacterial Infections; Critical Illness
    Interventions
    Ceftazidime-avibactam
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2017-03-13
    Completion
    2020-10-21
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Failure; Bacterial Infections; Critical Illness
    InterventionCeftazidime-avibactam
    PhaseNot recorded
    Registry statusUnknown

  • Aztreonam for Inhalation Solution (AZLI) for the Treatment of Exacerbations of Cystic Fibrosis

    NCT02894684 · start 2017-01

    Registered record
    Registry ID
    NCT02894684
    Conditions
    Cystic Fibrosis; Infection; Pseudomonas
    Interventions
    Aztreonam; Standard Care
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-01
    Completion
    2019-09
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis; Infection; Pseudomonas
    InterventionAztreonam; Standard Care
    PhasePhase 4
    Registry statusCompleted

  • The Efficacy of Prolonged Antibiotic Therapy for the Prevention of Relapsing Peritonitis in Peritoneal Dialysis Patients With High Dialysis Effluent Bacterial DNA Fragment Levels

    NCT02593201 · start 2016-02-26

    Registered record
    Registry ID
    NCT02593201
    Conditions
    Peritoneal Dialysis
    Interventions
    Extended antibiotics (cefazolin or ceftazidime); Usual antibiotics (cefazolin or ceftazidime)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-02-26
    Completion
    2019-06-30
    Enrolment
    358

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPeritoneal Dialysis
    InterventionExtended antibiotics (cefazolin or ceftazidime); Usual antibiotics (cefazolin or ceftazidime)
    PhasePhase 4
    Registry statusCompleted

  • Evaluation of Safety, Pharmacokinetics and Efficacy of Ceftazidime and Avibactam (CAZ-AVI ) Compared With Cefepime in Children From 3 Months to Less Than 18 Years of Age With Complicated Urinary Tract Infections (cUTIs)

    NCT02497781 · start 2015-09-24

    Registered record
    Registry ID
    NCT02497781
    Conditions
    Complicated Urinary Tract Infections
    Interventions
    Ceftazidime -avibactam; Cefepime
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-09-24
    Completion
    2017-09-15
    Enrolment
    97

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionComplicated Urinary Tract Infections
    InterventionCeftazidime -avibactam; Cefepime
    PhasePhase 2
    Registry statusCompleted